作者
Nikola Mitrev, N Vande Casteele, Cynthia H Seow, JM Andrews, SJ Connor, GT Moore, M Barclay, J Begun, R Bryant, W Chan, Crispin Corte, S Ghaly, DA Lemberg, Viraj Kariyawasam, P Lewindon, J Martin, R Mountifield, G Radford‐Smith, Peter Slobodian, M Sparrow, Catherine Toong, D Van Langenberg, MG Ward, RW Leong, IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group
发表日期
2017/12
来源
Alimentary pharmacology & therapeutics
卷号
46
期号
11-12
页码范围
1037-1053
简介
Background
Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes. Consensus statements based on current evidence will help the development of treatment guidelines.
Aim
To develop evidence‐based consensus statements for TDM‐guided anti‐TNF therapy in IBD.
Methods
A committee of 25 Australian and international experts was assembled. The initial draft statements were produced following a systematic literature search. A modified Delphi technique was used with 3 iterations. Statements were modified according to anonymous voting and feedback at each iteration. Statements with 80% agreement without or with minor reservation were accepted.
Results
22/24 statements met criteria for consensus. For anti‐TNF agents, TDM should be performed upon treatment failure, following successful …
学术搜索中的文章
N Mitrev, N Vande Casteele, CH Seow, JM Andrews… - Alimentary pharmacology & therapeutics, 2017